A mid-September 2026 briefing noted that macro conditions in mid-July 2026 were shaped by escalating military tensions around the Strait of Hormuz, which drove Asian LNG spot prices up 10% to $20.2/MMBtu — the highest level since March — contributing to broader equity market pressure during the European session [Brief - 2026-09-11]. These developments formed part of the broader market backdrop against which Abbott Laboratories was trading during the period.
As of the quarter ending 31 March 2026, Abbott Laboratories reported trailing twelve-month revenue of $45.13 billion, representing year-over-year growth of 7.78% [SEC 10-Q - ABT - 2026-03-31]. Net income over the same period was $6.28 billion, with a net margin of 13.91% and an operating margin of 17.07%. Gross margin stood at 37.08%. EPS declined 19.74% year-over-year. The company held $6.80 billion in cash against total debt of $29.64 billion, and the trailing P/E ratio was recorded at 28.74 [SEC 10-Q - ABT - 2026-03-31].
Insider activity over the past 30 days recorded seven transactions with a net direction of selling, totalling a net disposal value of approximately $46.21 million [SEC Form 4 - ABT - 2026-09]. On the institutional side, five notable firms opened new positions in Abbott Laboratories during the most recent 13F reporting period: Citadel (Ken Griffin), Millennium (Izzy Englander), AQR Capital (Cliff Asness), Bridgewater (Ray Dalio), and Soros Fund Management (George Soros) each initiated new holdings [SEC 13F - Citadel - Q2 2026; SEC 13F - Millennium - Q2 2026; SEC 13F - AQR Capital - Q2 2026; SEC 13F - Bridgewater - Q2 2026; SEC 13F - Soros Fund Mgmt - Q2 2026].
The prevailing macro environment shows the 10-year US Treasury yield at 4.94% and the 2-year yield at 4.67%, producing a normal yield curve spread of 27 basis points [FRED DGS10; FRED DGS2]. This configuration reflects the current interest rate backdrop within which Abbott's debt position of $29.64 billion and cash holdings of $6.80 billion are situated [SEC 10-Q - ABT - 2026-03-31].
This report was generated in response to material institutional position changes, specifically the simultaneous opening of new positions by five major institutional managers as disclosed in their most recent 13F filings [SEC 13F - Citadel - Q2 2026; SEC 13F - Millennium - Q2 2026; SEC 13F - AQR Capital - Q2 2026; SEC 13F - Bridgewater - Q2 2026; SEC 13F - Soros Fund Mgmt - Q2 2026].